{"DataElement":{"publicId":"6346981","version":"1","preferredName":"Transplant Conditioning Regimen Type","preferredDefinition":"Information related to the type of conditioning regimen used to prepare a person for receipt of a transplant.","longName":"2198273v1.0:6346963v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"2198273","version":"1","preferredName":"Transplant Conditioning Regimen","preferredDefinition":"A treatment plan to prepare a person for receipt of a transplant.","longName":"TSPL_COND_RGM","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2206967","version":"1","preferredName":"Transplant Conditioning","preferredDefinition":"Healthy skin, bone, or other tissue taken from one part of the body and used to replace diseased or injured tissue removed from another part of the body.:Generally refers to relative simple learning situations in which a stimulus initially incapable of evoking a certain response acquires the ability to do so by repeated pairing with another stimulus that does elicit the response.","longName":"C12981:C41258","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graft","conceptCode":"C12981","definition":"Tissue or organ transplanted from a donor to a recipient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Conditioning","conceptCode":"C41258","definition":"Generally refers to relative simple learning situations in which a stimulus initially incapable of evoking a certain response acquires the ability to do so by repeated pairing with another stimulus that does elicit the response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-1262-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177402","version":"1","preferredName":"Regimen","preferredDefinition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","longName":"Regimen","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-527D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEFD9E97-FD88-0048-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-02-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6346963","version":"1","preferredName":"Transplant Conditioning Regimen Type","preferredDefinition":"The type of conditioning regimen used to prepare a person for receipt of a transplant.","longName":"6346963v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"ALPHANUMERIC","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Fludarabine/Busulfan","valueDescription":"Fludarabine Busulfan","ValueMeaning":{"publicId":"6346964","version":"1","preferredName":"Fludarabine Busulfan","longName":"6346964","preferredDefinition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04): A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Busulfan","conceptCode":"C321","definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"709604DD-BD2F-5A62-E053-F662850A73F1","latestVersionIndicator":"Yes","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"709604DD-BD48-5A62-E053-F662850A73F1","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","deletedIndicator":"No"},{"value":"Busulfan/Melphalan","valueDescription":"Busulfan/Melphalan Regimen","ValueMeaning":{"publicId":"6346965","version":"1","preferredName":"Busulfan/Melphalan Regimen","longName":"6346965","preferredDefinition":"A chemotherapeutic regimen composed of busulfan and melphalan used as a conditioning regimen for stem cell transplantation (SCT).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Busulfan/Melphalan Regimen","conceptCode":"C126792","definition":"A chemotherapeutic regimen composed of busulfan and melphalan used as a conditioning regimen for stem cell transplantation (SCT).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"709604DD-BD54-5A62-E053-F662850A73F1","latestVersionIndicator":"Yes","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"709604DD-BD6D-5A62-E053-F662850A73F1","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","deletedIndicator":"No"},{"value":"Busulfan/Cyclophosphamide","valueDescription":"Busulfan Cyclophosphamide","ValueMeaning":{"publicId":"6346966","version":"1","preferredName":"Busulfan Cyclophosphamide","longName":"6346966","preferredDefinition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Busulfan","conceptCode":"C321","definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"709604DD-BD7A-5A62-E053-F662850A73F1","latestVersionIndicator":"Yes","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"709604DD-BD93-5A62-E053-F662850A73F1","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","deletedIndicator":"No"},{"value":"Etoposide/Total body irradiation","valueDescription":"Etoposide Total-Body Irradiation","ValueMeaning":{"publicId":"6346967","version":"1","preferredName":"Etoposide Total-Body Irradiation","longName":"6346967","preferredDefinition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): Radiation therapy to the entire body. It is usually followed by bone marrow or peripheral stem cell transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Total-Body Irradiation","conceptCode":"C15350","definition":"A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"709604DD-BDA0-5A62-E053-F662850A73F1","latestVersionIndicator":"Yes","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"709604DD-BDB9-5A62-E053-F662850A73F1","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","deletedIndicator":"No"},{"value":"Cyclophosphamide/Total body irradiation","valueDescription":"Cyclophosphamide Total-Body Irradiation","ValueMeaning":{"publicId":"6346968","version":"1","preferredName":"Cyclophosphamide Total-Body Irradiation","longName":"6346968","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.: Radiation therapy to the entire body. It is usually followed by bone marrow or peripheral stem cell transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Total-Body Irradiation","conceptCode":"C15350","definition":"A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"709604DD-BDC6-5A62-E053-F662850A73F1","latestVersionIndicator":"Yes","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"709604DD-BDDF-5A62-E053-F662850A73F1","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"5170771","version":"1","preferredName":"Other","longName":"5170771","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E4D2332-841D-A760-E050-BB89AD43734F","latestVersionIndicator":"Yes","beginDate":"2016-03-18","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"709604DD-BDE9-5A62-E053-F662850A73F1","beginDate":"2016-11-15","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"709604DD-BD15-5A62-E053-F662850A73F1","latestVersionIndicator":"Yes","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"MORENOC","dateModified":"2018-10-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Transplant conditioning regim","type":"Preferred Question Text","description":"Transplant conditioning regimen","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70963026-4B6B-5C2C-E053-F662850A8939","latestVersionIndicator":"Yes","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"MORENOC","dateModified":"2018-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}